Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.56 |
| ▸ | CASP7 | P55210 | 9/20 | 0.50 |
| ▸ | CASP1 | P29466 | 7/20 | 0.50 |
| ▸ | CASP9 | P55211 | 4/20 | 0.50 |
| ▸ | CASP4 | P49662 | 3/20 | 0.49 |
| ▸ | CASP5 | P51878 | 2/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.45 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052411 | 0.92 | CASP3 (0.66) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18472720 | 0.92 | CASP3 (0.66) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18471375 | 0.91 | CASP3 (0.59) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL19015955 | 0.90 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL19015923 | 0.89 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL20052415 | 0.86 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL20052436 | 0.86 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18471432 | 0.86 | CASP3 (0.66) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18471954 | 0.81 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18782202 | 0.81 | CASP3 (0.53) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.